Skip to content

Advertisement

  • Oral presentation
  • Open Access

HIV-1 pathogenesis: IFN-alpha-dependent and -independent mechanisms of T cell death and unresponsiveness

  • 1, 2,
  • 1,
  • 1 and
  • 1
Retrovirology20063 (Suppl 1) :S44

https://doi.org/10.1186/1742-4690-3-S1-S44

  • Published:

Keywords

  • Plasmacytoid Dendritic Cell
  • Immunologic Characteristic
  • Functional Unresponsiveness
  • Trail Expression
  • Selective Apoptosis

Functional unresponsiveness and numerical depletion of CD4+ T cells are immunologic characteristics of HIV-1 disease progression. Analyses of these poorly-understood phenomena by our laboratory indicate that both infections and noninfectious HIV-1 bind to and activate CD4+ plasmacytoid dendritic cells (pDC) to express: (1) interferon-alpha (IFN-alpha); and (2) indoleamine 2,3-dioxygenase (IDO). We found that HIV-induced IFN-alpha bound its receptor INFAR2 on CD4+ T cells, inducing expression of the death molecule TNF-Related Apoptosis-Inducing Ligand (TRAIL) by CD4+ T cells. The binding of infectious or noninfectious HIV-1 to CD4+ T cells induced expression of the TRAIL death receptor DR5, resulting in selective apoptosis of CD4+ T cells. IDO is a tryptophan-catabolizing enzyme that depletes T cells of tryptophan, resulting in their unresponsiveness. We found that HIV-induced expression of IDO by pDC activated the GCN2 stress response kinase in T cells, resulting in inhibition of both CD4+ and CD8+ T cell function. This effect of IDO on both T cell subsets contrasts with expression of TRAIL and DR5, which is limited to CD4+ T cells and their death. Anti-IFN-alpha antibody blocked IFN-alpha production by pDC and TRAIL expression by CD4+ T cells, but not expression of IDO by pDC. Blocking of HIV-1 binding to CD4 on pDC inhibited their expression of both IFN-alpha and IDO. Our comparative analyses reveal similarities and differences in HIV-induced mechanisms that contribute to T cell death and unresponsiveness.

Authors’ Affiliations

(1)
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
(2)
UMR CNRS 8147, Université Paris, Hopital Necker, Paris, France

Copyright

Advertisement